(Q30381923)

English

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

immune responsiveness

1 reference

based on heuristic

inferred from title

François Roman

5

object named as

François Roman

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

7

object named as

Paul Gillard

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

6

object named as

Mamadou Dramé

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

author name string

Tino F Schwarz

1

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Thomas Horacek

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Markus Knuf

3

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Hanns-Gerd Damman

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Wolfgang Jilg

8

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work or name

0 references

publication date

1 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

6284-6290

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Avian influenza virus (H5N1): a threat to human health.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Human infection with highly pathogenic H5N1 influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Update on avian influenza A (H5N1) virus infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Mitigation strategies for pandemic influenza in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Strategies for mitigating an influenza pandemic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Pre- or post-pandemic influenza vaccine?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Pandemic H5N1 influenza vaccine development: an update.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.040

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.01.040

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30381923&oldid=1549962827"